The deal, which includes an $800-million upfront payment and an additional contingent payment of $250-million on achieving a specified regulatory milestone, is expected to close by the third quarter of 2024
said on Thursday it would acquire endocrine diseases-focused firm Amolyt Pharma for $1.05-billion in cash, in a bid to boost its rare diseases portfolio.
. Eneboparatide, which is expected to be launched next year, has blockbuster potential, Alexion CEO Marc Dunoyer told Reuters in an interview.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
KKR Considers Selling Stake in India’s $3 Billion JB Pharma, Sources SayKKR & Co. is exploring options including selling its controlling stake in India’s JB Chemicals & Pharmaceuticals Ltd. amid interest from potential buyers, according to people familiar with the matter.
Lire la suite »
Vancouver readies for its position as a global pharma capital as B.C.'s biotech boom takes offVancouver’s life sciences scene dates to the first biotech boom in the early 1980s. Toronto and Montreal also produced biotechs, but Vancouver had several advantages, such as risk-tolerant investors and the city’s natural beauty
Lire la suite »
Expected funding boost for Ontario universities a 'drop in the bucket,' critics sayThe W.P. McGee Trophy for the U Sports men's basketball champion at Carleton University in March 2023.
Lire la suite »
Private school executives boost Tory fundraising numbersExecutives of private schools that partnered with public colleges have donated over $151,000 to the Progressive Conservatives since 2018, according to corporate records and Elections Ontario data.
Lire la suite »
Niger Cuts Oil Minister’s Portfolio as It Sees Boost to OutputNiger slimmed its petroleum minister’s portfolio in a government reshuffle as it seeks to boost oil output with a new pipeline, which came online last year.
Lire la suite »